[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1254573A1 - 包含苯基氨基嘧啶衍生物的藥物組合物 - Google Patents

包含苯基氨基嘧啶衍生物的藥物組合物

Info

Publication number
HK1254573A1
HK1254573A1 HK18113869.1A HK18113869A HK1254573A1 HK 1254573 A1 HK1254573 A1 HK 1254573A1 HK 18113869 A HK18113869 A HK 18113869A HK 1254573 A1 HK1254573 A1 HK 1254573A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
phenylaminopyrimidine derivative
phenylaminopyrimidine
derivative
pharmaceutical
Prior art date
Application number
HK18113869.1A
Other languages
English (en)
Inventor
Durga Maheswari Parvataneni
Mitrabhanu Mohanty
Venkata Satyanarayana Appadwedula
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of HK1254573A1 publication Critical patent/HK1254573A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18113869.1A 2015-12-18 2018-10-30 包含苯基氨基嘧啶衍生物的藥物組合物 HK1254573A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6951CH2015 2015-12-18
PCT/IN2016/050035 WO2017103941A1 (en) 2015-12-18 2016-01-30 Pharmaceutical compositions comprising phenylaminopyrimidine derivative

Publications (1)

Publication Number Publication Date
HK1254573A1 true HK1254573A1 (zh) 2019-07-19

Family

ID=59055898

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113869.1A HK1254573A1 (zh) 2015-12-18 2018-10-30 包含苯基氨基嘧啶衍生物的藥物組合物

Country Status (32)

Country Link
US (1) US10383872B2 (zh)
EP (1) EP3389633B1 (zh)
JP (2) JP6896738B2 (zh)
KR (1) KR20180102584A (zh)
CN (1) CN108495620B (zh)
AU (1) AU2016373574B2 (zh)
BR (1) BR112018012458A2 (zh)
CA (1) CA3008634A1 (zh)
CL (1) CL2018001590A1 (zh)
CO (1) CO2018007112A2 (zh)
CY (1) CY1124580T1 (zh)
DK (1) DK3389633T3 (zh)
EA (1) EA036513B1 (zh)
ES (1) ES2881883T3 (zh)
GB (1) GB2564262A (zh)
GE (1) GEP20207176B (zh)
HK (1) HK1254573A1 (zh)
HR (1) HRP20211590T1 (zh)
HU (1) HUE056269T2 (zh)
IL (1) IL260085B (zh)
LT (1) LT3389633T (zh)
MA (1) MA44079B1 (zh)
MX (1) MX2018007281A (zh)
PH (1) PH12018501292A1 (zh)
PL (1) PL3389633T3 (zh)
PT (1) PT3389633T (zh)
RS (1) RS62422B1 (zh)
SG (1) SG11201805142RA (zh)
SI (1) SI3389633T1 (zh)
UA (1) UA122592C2 (zh)
WO (1) WO2017103941A1 (zh)
ZA (1) ZA201804203B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物
CZ2017821A3 (cs) * 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7333340B2 (ja) * 2018-05-14 2023-08-24 キャプシュゲル・ベルジウム・エヌ・ヴィ 高い活性薬剤ローディングを有する固体剤形
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN115583634B (zh) * 2022-09-21 2023-06-06 广东工业大学 一种碳氮聚合物材料的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
EP2295424B1 (en) 2004-09-09 2015-10-14 Natco Pharma Limited Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
CN106029065A (zh) * 2013-12-20 2016-10-12 法斯瑞斯公司 靛玉红固体分散组合物

Also Published As

Publication number Publication date
EA201891443A1 (ru) 2019-01-31
HRP20211590T1 (hr) 2022-01-07
UA122592C2 (uk) 2020-12-10
CL2018001590A1 (es) 2018-11-30
US20190015412A1 (en) 2019-01-17
EP3389633B1 (en) 2021-07-14
GB2564262A (en) 2019-01-09
ZA201804203B (en) 2020-08-26
EP3389633A4 (en) 2019-08-07
PT3389633T (pt) 2021-08-05
CN108495620B (zh) 2021-09-03
BR112018012458A2 (pt) 2018-12-18
GEAP201614833A (zh) 2020-06-25
ES2881883T3 (es) 2021-11-30
CN108495620A (zh) 2018-09-04
EA036513B1 (ru) 2020-11-18
US10383872B2 (en) 2019-08-20
SG11201805142RA (en) 2018-07-30
CY1124580T1 (el) 2022-07-22
MX2018007281A (es) 2018-11-29
GEP20207176B (en) 2020-11-10
RS62422B1 (sr) 2021-10-29
MA44079B1 (fr) 2021-10-29
AU2016373574B2 (en) 2021-10-14
EP3389633A1 (en) 2018-10-24
JP6896738B2 (ja) 2021-06-30
AU2016373574A1 (en) 2018-07-12
GB201811142D0 (en) 2018-08-22
DK3389633T3 (da) 2021-08-30
JP2021059551A (ja) 2021-04-15
PH12018501292A1 (en) 2019-02-04
CA3008634A1 (en) 2017-06-22
HUE056269T2 (hu) 2022-02-28
CO2018007112A2 (es) 2018-07-19
IL260085B (en) 2021-09-30
MA44079A (fr) 2021-04-21
WO2017103941A1 (en) 2017-06-22
IL260085A (en) 2018-07-31
JP2018538325A (ja) 2018-12-27
PL3389633T3 (pl) 2021-12-13
LT3389633T (lt) 2021-09-10
KR20180102584A (ko) 2018-09-17
SI3389633T1 (sl) 2021-11-30

Similar Documents

Publication Publication Date Title
HK1225655A1 (zh) 包含azd9291的藥用組合物
GB201419257D0 (en) Pharmaceutical compositions
GB201618482D0 (en) Pharmaceutical compositions
IL249553A0 (en) Pharmaceutical preparations
GB201608323D0 (en) Pharmaceutical compositions
IL271759A (en) Pharmaceutical preparations that include anthraxtinib
HK1254573A1 (zh) 包含苯基氨基嘧啶衍生物的藥物組合物
GB201521462D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
HK1245073A1 (zh) 藥物組合物
IL250817A0 (en) pharmaceutical preparations
GB201520862D0 (en) Pharmaceutical composition
IL263999A (en) Pharmaceutical compositions
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
ZA201705782B (en) Pharmaceutical compositions
ZA201705783B (en) Pharmaceutical compositions
GB201700831D0 (en) Pharmaceutical compositions
PL3319596T3 (pl) Farmaceutyczne kompozycje
GB201506598D0 (en) Pharmaceutical compositions
GB201520762D0 (en) Novel pharmaceutical compositions
GB201521456D0 (en) Pharmaceutical composition
SG2014014872A (en) Pharmaceutical compositions
GB201408432D0 (en) Pharmaceutical compositions